Management of allergic rhinitis in the era of effective over-the-counter treatments

References

• Benninger MS, Hadley JA, Osguthorpe JD, et al. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg. 2004;130(1):5–24.
   PubMed Web of Science ®Google Scholar
• Compalati E, Ridolo E, Passalacqua G, et al. The link between allergic rhinitis and asthma: the united airways disease. Expert Rev Clin Immunol. 2010;6(3):413–423. Epub 2010/05/06.
   PubMed Web of Science ®Google Scholar
• Blaiss MS, Meltzer EO, Derebery MJ, et al. Patient and healthcare-provider perspectives on the burden of allergic rhinitis. Allergy Asthma Proc. 2007;28(Suppl 1):S4–10.
   PubMed Web of Science ®Google Scholar
• De La Hoz Caballer B, Rodríguez M, Fraj J, et al. Allergic rhinitis and its impact on work productivity in primary care practice and a comparison with other common diseases: the Cross-sectional study to evAluate work Productivity in allergic Rhinitis compared with other common dIseases (CAPRI) study. Am J Rhinol Allergy. 2012;26(5):390–394. Epub 2012/11/22.
   PubMed Web of Science ®Google Scholar
• Fromer LM, Blaiss MS, Jacob-Nara JA, et al. Current Allergic Rhinitis Experiences Survey (CARES): consumers’ awareness, attitudes and practices. Allergy Asthma Proc. 2014;35(4):307–315. Epub 2014/07/06.
   PubMed Web of Science ®Google Scholar
• Blaiss MS, Dykewicz MS, Skoner DP, et al. Diagnosis and treatment of nasal and ocular allergies: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Ann Allergy Asthma Immunol. 2014;112(4):322–8e1. Epub 2014/04/01.
   PubMed Web of Science ®Google Scholar
• Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1Suppl):S1–43. Epub 2015/02/04.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–476. Epub 2010/09/08.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl 86):8–160.
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):S1–84.
   PubMed Web of Science ®Google Scholar
• Valovirta E, Ryan D. Patient adherence to allergic rhinitis treatment: results from patient surveys. Medscape J Med. 2008;10(10):247.
   PubMedGoogle Scholar
• Mortuaire G, De Gabory L, François M, et al. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(3):137–144. Epub 2013/02/05.
   PubMed Web of Science ®Google Scholar
• Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy. 2007;62(9):1057–1063. Epub 2007/06/22.
   PubMed Web of Science ®Google Scholar
• Bernstein JA. Allergic and mixed rhinitis: epidemiology and natural history. Allergy Asthma Proc. 2010;31(5):365–369. Epub 2010/10/12.
   PubMed Web of Science ®Google Scholar
• Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. 2011/05/28 ed2011.
   Google Scholar
• Newacheck PW, Taylor WR. Childhood chronic illness: prevalence, severity, and impact. Am J Public Health. 1992;82(3):364–371. Epub 1992/03/01.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(2 Suppl):S12–S16.
   PubMed Web of Science ®Google Scholar
• Blaiss MS. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc. 2010;31(5):375–380. Epub 2010/10/12.
   PubMed Web of Science ®Google Scholar
• Stempel DA, Woolf R. The cost of treating allergic rhinitis. Curr Allergy Asthma Rep. 2002;2(3):223–230. Epub 2002/03/29.
   PubMedGoogle Scholar
• Wang D-Y. Risk factors of allergic rhinitis: genetic or environmental? Ther Clin Risk Manag. 2005;1(2):115–123. Epub 2008/03/25.
   PubMedGoogle Scholar
• Berrettini S, Carabelli A, Sellari-Franceschini S, et al. Perennial allergic rhinitis and chronic sinusitis: correlation with rhinologic risk factors. Allergy. 1999;54(3):242–248. Epub 1999/05/13.
   PubMed Web of Science ®Google Scholar
• Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007;62(suppl 85):9–16.
   PubMed Web of Science ®Google Scholar
• Allergies in America: a landmark survey of nasal allergy sufferers. Executive summary: Sepracor; [ cited 2008 June 3]. Available from: http://www.worldallergy.org/UserFiles/file/Allergies%20in%20America%20(AIA)%20-%20Adult%20Executive%20Summary.pdf
   Google Scholar
• Bousquet PJ, Bousquet-Rouanet L, Co Minh HB, et al. ARIA (Allergic Rhinitis and Its Impact on Asthma) classification of allergic rhinitis severity in clinical practice in France. Int Arch Allergy Immunol. 2007;143(3):163–169. Epub 2007/02/08.
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Demoly P, Devillier P, et al. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160(4):393–400. Epub 2012/11/28.
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Bachert C, Canonica GW, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126(3):666-8e1-5. Epub 2010/09/08.
   Web of Science ®Google Scholar
• Smith AF, Pitt AD, Rodruiguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol. 2005;12(4):233–242. Epub 2005/07/22.
   PubMed Web of Science ®Google Scholar
• Lu D, Zhao Y, Zheng Y, et al. Evaluation of quality of life questionnaires for adult patients with moderate to severe allergic rhinitis. Am J Otolaryngol. 2011;32(6):494–498. Epub 2010/11/26.
   PubMed Web of Science ®Google Scholar
• Colás C, Galera H, Añibarro B, et al. Disease severity impairs sleep quality in allergic rhinitis (The SOMNIAAR study). Clin Exp Allergy. 2012;42(7):1080–1087. Epub 2012/01/19.
   PubMed Web of Science ®Google Scholar
• Tanner LA, Reilly M, Meltzer EO, et al. Effect of fexofenadine HCI on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manag Care. 1999;5(4 Suppl):S235–S247.
   Web of Science ®Google Scholar
• Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005;4(6):439–446.
   PubMedGoogle Scholar
• Thompson A, Sardana N, Craig TJ. Sleep impairment and daytime sleepiness in patients with allergic rhinitis: the role of congestion and inflammation. Ann Allergy Asthma Immunol. 2013;111(6):446–451. Epub 2013/11/26.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Blaiss MS, Jennifer DM, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol. 2009;124(suppl 3):S43–S70.
   PubMed Web of Science ®Google Scholar
• Vuurman EF, Van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy. 1993;71(2):121–126.
   PubMedGoogle Scholar
• Spector SL, Nicklas RA, Chapman JA, et al. Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol. 2003;91(2):105–114.
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62(4):367–372. Epub 2007/03/17.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Investig. 1996;11(5):278–288.
   Web of Science ®Google Scholar
• Work productivity and activity impairment questionnaire plus classroom impairment questions: allergy specific (WPAI+CIQ:AS): Reilly Associates; 2016 [2017 February 9]. Available from: http://www.reillyassociates.net/WPAI_AS.html
   Google Scholar
• Spinozzi F, Murgia N, Baldacci S, et al. Characteristics and predictors of allergic rhinitis undertreatment in primary care. Int J Immunopathol Pharmacol. 2016;29(1):129–136. Epub 2015/12/19.
   PubMed Web of Science ®Google Scholar
• Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg. 2007;136(6Suppl):S107–24. Epub 2007/05/22.
   PubMed Web of Science ®Google Scholar
• Köberlein J, Kothe AC, Schaffert C. Determinants of patient compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11(3):192–199.
   PubMed Web of Science ®Google Scholar
• Kumar R, Kumar D, Parakh A. Fluticasone furoate: a new intranasal corticosteroid. J Postgrad Med. 2012;58(1):79–83. Epub 2012/03/06.
   PubMed Web of Science ®Google Scholar
• Angier E, Willington J, Scadding G, et al. Management of allergic and non-allergic rhinitis: a primary care summary of the BSACI guideline. Prim Care Respir J. 2010;19(3):217–222. Epub 2010/08/04.
   PubMedGoogle Scholar
• Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J. 2006;15(1):58–70.
   PubMedGoogle Scholar
• Members of the Workshops. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy. 2004;59(4):373–387. Epub 2004/03/10.
   PubMed Web of Science ®Google Scholar
• Empowering patients to navigate OTC allergic rhinitis therapy: practical points for the pharmacist. Pharm Times. 2016. Available from: http://www.pharmacytimes.com/publications/issue/2016/february2016/r754_february2016
   Google Scholar
• Singulair [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2015.
   Google Scholar
• Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med. 2001;161(21):2581–2587. Epub 2001/12/26.
   PubMed Web of Science ®Google Scholar
• Berlin JM, Golden SJ, Teets S, et al. Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis. J Am Osteopath Assoc. 2000;100(7Suppl):S8–13. Epub 2000/08/19.
   PubMedGoogle Scholar
• Ratner PH, van Bavel JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract. 1998;47(2):118–125. Epub 1998/09/02.
   PubMed Web of Science ®Google Scholar
• Jordana G, Dolovich J, Briscoe MP, et al. Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97(2):588–595. Epub 1996/02/01.
   PubMed Web of Science ®Google Scholar
• Andrews CP, Martin BG, Jacobs RL, et al. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009;30(2):128–138. Epub 2009/05/26.
   PubMed Web of Science ®Google Scholar
• Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010;104(1):13–29. Epub 2010/02/11.
   PubMed Web of Science ®Google Scholar
• Patel P, Patel D. Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. Ann Allergy Asthma Immunol. 2008;101(3):287–294.
   PubMed Web of Science ®Google Scholar
• Martin BG, Andrews CP, van Bavel JH, et al. Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol. 2006;96(6):851–857. Epub 2006/06/29.
   PubMed Web of Science ®Google Scholar
• Williams A, Scadding G. Is reliance on self-medication and pharmacy care adequate for rhinitis patients? Int J Clin Pract. 2009;63(1):98–104. Epub 2009/01/08.
   PubMed Web of Science ®Google Scholar
• Harrington P, Shepherd MD. Analysis of the movement of prescription drugs to over-the-counter status. J Manag Care Pharm. 2002;8(6):499-508; quiz 509-11. Epub 2003/11/14.
   PubMedGoogle Scholar
• Nasacort [summary of product characteristics France]. Gentilly, France: Sanofi Aventis France; 2016.
   Google Scholar
• Flonase Allergy Relief approved label: U.S. Food and Drug Administration; 2014 [2016 May 25]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205434Orig1s000Lbl.pdf
   Google Scholar
• Rhinocort Allergy approved label: U.S. Food and Drug Administration; 2016 [2016 May 25]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020746Orig1s034lbl.pdf
   Google Scholar
• Flonase® Sensimist™ Allergy Relief approved label: U.S. Food and Drug Administration; 2017 [2017 April 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022051Orig1s014lbl.pdf
   Google Scholar
• Claritin 24 Hour Tablets approved label: U.S. Food and Drug Administration; 2017 [2017 Apr 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020746Orig1s036lbl.pdf
   Google Scholar
• Zyrtec [product description]: Johnson & Johnson Consumer; 2015 [2016 August 1]. Available from: https://www.zyrtec.com/products/zyrtec-tablets
   Google Scholar
• Allegra-D drug facts label: sanofi; 2016 [2017 May 5]. Available from: http://otc.allegra.com/hcp/
   Google Scholar
• Claritin-D 24 Hour Tablets approved label: U.S. Food and Drug Administration; 2015 [2015 Nov 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019670Orig1s032,%20020470Orig1s044lbl.pdf
   Google Scholar
• Zyrtec-D [product description]: Johnson & Johnson Consumer; 2015 [2016 August 1]. Available from: https://www.zyrtec.com/products/zyrtec-d
   Google Scholar
• Nasalcrom Nasal Allergy Spray [package insert]. Tarrytown, NY: Prestige Brands, Inc.; 2016.
   Google Scholar
• Meltzer EO, Ratner PH, McGraw T. Oral phenylephrine HCl for nasal congestion in seasonal allergic rhinitis: a randomized, open-label, placebo-controlled study. J Allergy Clin Immunol Pract. 2015;3(5):702–708. Epub 2015/07/06.
   PubMed Web of Science ®Google Scholar
• Allegra-D [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2009.
   Google Scholar
• Meltzer EO, Farrar JR, Sennett C. Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US patients. J Allergy Clin Immunol Pract. 2016;5(3):779–789.e6. Epub 2016/12/05.
   PubMed Web of Science ®Google Scholar
• Hermelingmeier KE, Weber RK, Hellmich M, et al. Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2012;26(5):e119–25. Epub 2012/11/22.
   PubMed Web of Science ®Google Scholar
• Nasacort Allergy 24 HR supplement approval letter. Silver Spring, MD: Food and Drug Administration. 2013 [2016 August 1]. Available from http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020468Orig1s035ltr.pdf
   Google Scholar
• Flonase [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.
   Google Scholar
• Nasacort Allergy 24HR approved label: U.S. Food and Drug Administration; 2013 [2016 May 25]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020468Orig1s035lbl.pdf
   Google Scholar
• Hellings PW, Dobbels F, Denhaerynck K, et al. Explorative study on patient’s perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis. Clin Transl Allergy. 2012;2(1):9. Epub 2012/05/31.
   PubMedGoogle Scholar
• Blaiss MS. Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc. 2011;32(6):413–418. Epub 2012/01/10.
   PubMed Web of Science ®Google Scholar
• Jang TY, Kim YH. Recent updates on the systemic and local safety of intranasal steroids. Curr Drug Metab. 2016;17(10):992–996. Epub 2016/11/29.
   Web of Science ®Google Scholar
• Veramyst [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.
   Google Scholar
• Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105(2):E23.
   PubMed Web of Science ®Google Scholar
• Skoner DP, Berger WE, Gawchik SM, et al. Intranasal triamcinolone and growth velocity. Pediatrics. 2015;135(2):e348–56. Epub 2015/01/28.
   PubMed Web of Science ®Google Scholar
• Lee LA, Sterling R, Máspero J, et al. Growth velocity reduced with once-daily fluticasone furoate nasal spray in prepubescent children with perennial allergic rhinitis. J Allergy Clin Immunol Pract. 2014;2(4):421–427. Epub 2014/07/16.
   PubMed Web of Science ®Google Scholar
• Skoner DP. The tall and the short: repainting the landscape about the growth effects of inhaled and intranasal corticosteroids. Allergy Asthma Proc. 2016;37(3):180–191. Epub 2016/03/05.
   PubMed Web of Science ®Google Scholar
• Mahadevia PJ, Shah S, Leibman C, et al. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis. Ann Allergy Asthma Immunol. 2004;93(4):345–350. Epub 2004/11/04.
   PubMed Web of Science ®Google Scholar
• Mahadevia P, Shah S, Mannix S, et al. Willingness to pay for sensory attributes of intranasal corticosteroids among patients with allergic rhinitis. J Manag Care Pharm. 2006;12(2):143–151. Epub 2006/03/07.
   PubMed Web of Science ®Google Scholar
• Fromer LM, Ortiz G, Ryan SF, et al. Insights on allergic rhinitis from the patient perspective. J Fam Pract. 2012;61(2Suppl):S16–22. Epub 2012/02/15.
   PubMedGoogle Scholar
• Gross GN, Settipane RA, Ford LB, et al. Patient satisfaction with beclomethasone dipropionate nasal aerosol device with integrated dose counter during daily use. Allergy Asthma Proc. 2013;34(6):527–533.
   PubMed Web of Science ®Google Scholar
• Stokes M, Amorosi SL, Thompson D, et al. Evaluation of patients’ preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg. 2004;131(3):225–231. Epub 2004/09/15.
   PubMed Web of Science ®Google Scholar
• Yonezaki M, Akiyama K, Karaki M, et al. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis. Auris Nasus Larynx. 2016;43(3):292–297. Epub 2015/10/27.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Andrews C, Journeay GE, et al. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol. 2010;104(4):331–338. Epub 2010/04/23.
   PubMed Web of Science ®Google Scholar
• QNASL [package insert]. Horsham, PA: Teva Respiratory, LLC; 2014.
   Google Scholar
• Dymista [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; 2015.
   Google Scholar
• Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282–1289.e10. Epub 2012/03/16.
   PubMed Web of Science ®Google Scholar
• Flonase [package insert]. Research Triangle Park, NC : GlaxoSmithKline; 2004.
   Google Scholar